Maxim Group analyst, Jason Kolbert, reiterated his Buy rating on shares of Adamis Pharmaceuticals (NASDAQ: ADMP) after Auvi-Q (Kaleo, a ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE